NPPB and cardiovascular disorder: Results were not meaningfully changed in sensitivity analyses that (1) removed any incident HF event occurring within 1 year of infection to minimize the potential for reverse causality (Table S2); or (2) included additional adjustments for cardiovascular disease medications, C‐reactive protein, or NT‐proBNP (N‐ terminal pro‐B‐type natriuretic peptide; Table S3).